# Venatorx Pharmaceuticals Inc.

Canonical: https://abierto.us/vendors/venatorx-pharmaceuticals-inc-mbbknbu5dcc6

- UEI: MBBKNBU5DCC6
- CAGE: 61SY9
- Location: Malvern, PA
- Awards in window: 6 (31 transactions), $40,477,464 obligated, January 19, 2024 to September 14, 2026

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 3 awards, $31,255,006
- National Institutes of Health: 2 awards, $9,682,676
- Defense Threat Reduction Agency: 1 awards, -$460,217

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $31,255,006
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $9,663,738
- 541711 Professional, Scientific, and Technical Services: -$441,280

## Competition

- Full and Open Competition: 6 awards

## Largest awards

- 75A50123C00050 (definitive contract): $24,870,405, Barda - Aspr / Daappo / Barda DCMA. The Purpose of This Modification Is to Update Article G.7 Indirect Cost Rate. https://www.usaspending.gov/award/CONT_AWD_75A50123C00050_7505_-NONE-_-NONE-/
- 75N93020C00016 (definitive contract): $9,663,738, National Institutes of Health Niaid. Non Beta-Lactam Inhibitors of Penicillin Binding Proteins Targeting Mdr-Acinetobacter Baumannii.. https://www.usaspending.gov/award/CONT_AWD_75N93020C00016_7529_-NONE-_-NONE-/
- 75A50119C00007 (definitive contract): $6,384,601, Barda - Aspr / Daappo / Barda DCMA. The Purpose of This Modification Is to Correct the Period of Performance for Clin0007 to Align with Ipp.. https://www.usaspending.gov/award/CONT_AWD_75A50119C00007_7505_-NONE-_-NONE-/
- HHSN272201600029C (definitive contract): $18,938, National Institutes of Health Niaid. The Purpose of This Contract Is the Development of a Novel Orally Bioavailable Beta-Lactamase Inhibitor Through Delivery to the Government Of: CMC and Preliminary Non-Clinical Development (Clin 001); a Beta-Lactam Clinical Study (Clin 002); a NON-GLP. https://www.usaspending.gov/award/CONT_AWD_HHSN272201600029C_7529_-NONE-_-NONE-/
- 75A50122C00080 (definitive contract): $0, Barda - Aspr / Daappo / Barda DCMA. The Purpose of This Modification Is to Update Article G.12. Indirect Cost Rate. https://www.usaspending.gov/award/CONT_AWD_75A50122C00080_7505_-NONE-_-NONE-/
- HDTRA117C0070 (definitive contract): -$460,217, Defense Threat Reduction Agency. New PBP Inhibitors Impervious to Beta-Lactamases. https://www.usaspending.gov/award/CONT_AWD_HDTRA117C0070_9700_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/venatorx-pharmaceuticals-inc-mbbknbu5dcc6.